WO2002103025A1 - Nouveau saccharide sulfate et procede de production associe - Google Patents
Nouveau saccharide sulfate et procede de production associe Download PDFInfo
- Publication number
- WO2002103025A1 WO2002103025A1 PCT/JP2002/002716 JP0202716W WO02103025A1 WO 2002103025 A1 WO2002103025 A1 WO 2002103025A1 JP 0202716 W JP0202716 W JP 0202716W WO 02103025 A1 WO02103025 A1 WO 02103025A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sulfated
- represented
- general formula
- saccharide
- hydroxyl group
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H11/00—Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P11/00—Preparation of sulfur-containing organic compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
Definitions
- the present invention relates to a novel sulfated saccharide and a method for producing the same.
- Known sugars and glycolipids having a sulfate group in the molecule include sulfated Sialyl Lewis X and sulfatide, which can specifically bind to selectin proteins and the like present in leukocytes of humans and animals. Are known. Therefore, these sulfated saccharides exhibit selectin blockers and are expected to be applied to the development and application of pharmaceuticals such as anti-inflammatory drugs and prevention of cancer metastasis.
- the method (1) only a trace amount of the target substance is generally obtained.
- the method (3) provides a large amount of the target compound, the reaction step is generally long and requires a lot of labor.
- the method (2) has relatively many reports on the synthesis of saccharides having no sulfate group, but few examples of synthesis of saccharides having a sulfate group are known.
- the method (a) is characterized in that a transferase that transfers a sulfate group (sulfotransferase: sulfotransferase) is used, but the transferase used is expensive.
- sulfotransferase sulfotransferase
- the transferase used is expensive.
- the introduction position of the sulfate group is limited to the 6-position on the reducing end side, it is difficult to say that it is difficult to synthesize a sulfated saccharide having a sulfate group introduced on the non-reducing end side.
- the present inventors have used sulfated sugars as donors in the presence of N-acetylhexosaminidase or N-acetyl darcosaminidase as an enzyme, Was used as an acceptor, and when both were reacted, a sulfated sugar chain could be extended to the non-reducing end of the "other sugar". Also, similarly, sulfated sugar is used for the receptor,
- N-acetylhexosaminidase or N-acetyldarcosaminidase used in these methods is substantially the same enzyme, but the use of this enzyme can accelerate the reaction.
- This enzyme is easily available and has no economical problems. As a result, the above reaction can be carried out industrially advantageously.
- the sugar residue represented by [A] is glucose, galactose, mannose, N-acetyldarcosamine, N-acetylgalactosamine, N-acetylmannosamine or any of them.
- the sulfated saccharide according to the above (1) which is a saccharide residue derived from a saccharide selected from oligosaccharides composed of saccharides.
- the sugar residue represented by [C] in the general formula (I) is glucose, galactose, mannose, N-acetinoredalcosamine, N-acetinolegalactosamine, N-acetylmannosamine and the like.
- the sugar residue represented by [D] is glucose, galactose, mannose, N-acetyldarcosamine, N_acetylgalactosamine, N-acetylmannosamine or a sugar thereof.
- the sulfated saccharide according to the above (7) which is a saccharide residue derived from a saccharide selected from the following oligosaccharides.
- [A] one (6 SO 3 -G 1 cNAc) - [B] (la) (wherein, (6 S 0 3 _G 1 c NA c) ⁇ Pi [A] are as defined above, [ B] represents a substituted hydroxyl group or a sugar residue)
- N-acetylhexaminidase or N-acetylglucosami A method for producing an oxidized sugar chain represented by the general formula (I), wherein the reaction is carried out in the presence of an enzyme.
- [A] represents a hydroxyl group or a sugar residue.
- Sugar residues include residues derived from sugars selected from monosaccharides, oligosaccharides and polysaccharides.
- the monosaccharides include those conventionally known, for example, glucose, galactose, mannose, N-acetinolegnorrecosamine, N-acetylgalatatosamine, N-acetylmannosamine and the like.
- Oligosaccharides include those monosaccharides, chondroitin sulfate, Matane sulfate, heparin and the like are included.
- Polysaccharides include those obtained by highly polymerizing the aforementioned monosaccharides and oligosaccharides. These sugars may contain a sulfate group or a phosphate group.
- [C] represents a sugar residue.
- Sugar residues include residues derived from sugars selected from monosaccharides, oligosaccharides and polysaccharides.
- the monosaccharides include those conventionally known, for example, gnorecose, galactose, mannose, N-acetinol regolecosamine, N-acetylgalatatosamine, N-acetyl mannosamine and the like.
- Oligosaccharides include oligosaccharides composed of those monosaccharides, chondroitin sulfate, dermatan sulfate, heparin and the like.
- Polysaccharides include those in which the polysaccharides and oligosaccharides are highly polymerized. These brans may contain sulfate or phosphate groups.
- R represents a hydroxyl group or a substituted hydroxyl group.
- the substituted hydroxyl group means a group in which hydrogen in the hydroxyl group is substituted with a substituent, and is represented by -OR '.
- R represents a substituent
- the substituent R includes an aliphatic group or an aromatic group.
- An aliphatic group may have an unsaturated bond, and the number of carbon atoms is 1 to 4.
- Such aliphatic groups include methyl, ethyl, propyl, butyl and the like.
- Aromatic groups include phenyl and substituted phenyl. Examples of the substituted phenyl include those substituted with a nitro group or an alkoxy group.
- a preferred substituted phenyl is para-nitrophenyl-ortho-nitrophenyl.
- [D] represents a hydroxyl group, a substituted hydroxyl group or a sugar residue.
- Sugar residues include residues derived from sugars selected from monosaccharides, oligosaccharides and polysaccharides.
- monosaccharides include, for example, glucose, galactose, mannose, and N-acetate. Includes tilgalactosamine, N-acetylmannosamine and the like.
- Oligosaccharides include oligosaccharides composed of these monosaccharides, chondroitin sulfate, dermatan sulfate, heparin and the like.
- Polysaccharides include those obtained by highly polymerizing the above-mentioned monosaccharides and oligosaccharides. These sugars may contain a sulfate group or a phosphate group.
- the substituted hydroxyl group means a group in which hydrogen in the hydroxyl group is substituted with a substituent, and specific examples thereof include those described above.
- the sulfated saccharide represented by the general formula (I) according to the present invention has the following general formula (la)
- [B] and (6 S 0 3 _G 1 c NA c) bonding mode between may be either ⁇ binding and binding, [beta] is - attached to the 1-position of (6 S0 3 G 1 cNAc) .
- [B] If the residues derived from that Ru sugar selected from monosaccharides and oligosaccharides, the 2-position of the [B], 3-position, 4-position or 6-position with [6 -S 0 3 - G 1 c NA c] is bonded to position 1.
- positions [3], [4], or [6] other than position 1 of [B] are (6-S 0 3 —G l cNAc) is linked to the 1 position.
- the sulfated saccharide represented by the general formula (Ila) is a known compound, and its natural product And synthetic products are commercially available.
- [Gal] represents a galactose residue.
- the galactose residue [G a 1] is a glucose residue, a mannose residue, an N-acetyl dalcosamine residue, an N-acetyl galatatosamine residue or an N_ acetylethyl mannosamine residue, It can be substituted with a rigo sugar residue or the like.
- R 3 to R 6 are hydrogen, or one of R 3 to R 6 is a sulfate group, a phosphate group or a sugar residue, and the rest are hydrogen.
- the sugar residue include sugar residues derived from monosaccharides such as glucose and galactose, and sugar residues derived from oligosaccharides of those sugars.
- R 7 represents an alkyl group, a phenyl group, a substituted phenyl group, hydrogen or a sugar residue, one of R 8 to R reflexis a bond (one), and (6SO 3 —G l cNA c) at position 1 (position to which [B] of the structural formula Ia is bonded), and the rest shows hydrogen, one of which may be substituted with a sulfate group or a phosphate group .
- R 3 , R s O—, R 7 —, R 80 —, and R 1 (i O_ may be an axial arrangement or an equatorial arrangement.
- the binding mode between [A] and (6 _ S 0 3 ⁇ G 1 c NA c) is, alpha binding ⁇ Pi i3 may be any binding, [A 1 position and, - are bonded with 3 or 4 position of (6 SO 3 G 1 c NA c).
- the sixth, second, third or fourth position may be sulfurized or phosphorylated.
- the sulfated and phosphoric oxides of this saccharide include, for example, galactose in which the 3-position is sulfated and daliose in which the 6-position is phosphorylated.
- [C] represents a sugar residue.
- the saccharide residue includes a residue derived from a saccharide selected from a monosaccharide, an oligosaccharide and a polysaccharide.
- the polysaccharide include those conventionally known, for example, glucose, galactose, mannose, N-acetyldanorecosamine, N-acetylgalactosamine, N-acetylmannosamine and the like.
- Oligosaccharides include oligosaccharides composed of these monosaccharides, chondroitin sulfate, dermatan sulfate, heparin and the like.
- Polysaccharides include those obtained by highly polymerizing the aforementioned monosaccharides and oligosaccharides.
- R represents a hydroxyl group or a substituted hydroxyl group, and specific examples of the substituted hydroxyl group in this case include those described above.
- the hydroxyl group at the 1-position can be a substituted hydroxyl group.
- Examples of the substituted hydroxyl group in this case include those described above.
- R 12 represents hydrogen, a substituent or a sugar residue.
- One of R 13 to R 16 is a bond (one), and the rest represents hydrogen, one of which is a sugar residue or a sulfate group. It may be an acid group or the like.
- OR 13 may be NHAc.
- sugar giving the sugar residue [C] examples include the following.
- Rata toose galact topyranosyl ⁇ 1 ⁇ 4 darcoviranoside
- the sulfated saccharide of the general formula (la) and the saccharide of the general formula (la) are reacted.
- the reaction in this case is a reaction to transfer a sulfate group (S0 3) containing sugars.
- the raw materials are usually used in a molar ratio of 1 to 1, but either of them may be used in excess.
- the reaction is carried out in the liquid phase and the reaction temperature ranges from 0 to 80 ° C, preferably from room temperature to 50 ° C.
- the enzyme used is N-acetylhexosaminidase (or N-acetyl darcosaminidase).
- the enzyme can be derived from mold, calf organs, bacteria, beans, yeast or recombinant DNA.
- N-acetylhexosaminidase E. 3.2.1.52
- N-acetyl darcosaminidase EC 3.2.1.52
- Carriers include alginic acid resins, ribosomes and the like.
- the reaction is performed in the presence of a solvent.
- An aqueous medium is usually used as the solvent.
- reaction product After completion of the reaction, the reaction product can be obtained in an isolated yield of 1 to 80% based on the raw material. After completion of the reaction, the reaction product can be separated and purified by means such as reverse phase chromatography, molecular sieving, and ion exchange.
- a commonly used buffer such as a phosphate buffer, Tris-HCl buffer, and HEPES buffer is used.
- a hydrophilic organic solvent such as acetonitrile and methanol is also added to the buffer.
- the ratio is 0 to 90%, but preferably 10 to 50%.
- solvents such as toluene-diethyl ether are also used. However, in this case, it is a two-phase system.
- the reaction is carried out in a range from 0 ° C to 80 ° C. Desirably, the reaction is performed at around room temperature to 50 ° C.
- [Alpha] and - binding mode of (6S0 3 GlcNAc) is, o; binding and 3 rather good any binding of 1-position and the [A] - 3-position or 4-position and the bond (6S0 3 GlcNAc) are doing.
- the compound of the general formula (I) of the present invention is characterized in that it is obtained by treating a sulfated sugar as a sugar chain donor and using another sugar as a sugar chain acceptor. It is a structure with an elongated chain.
- the by-product corresponding to this target product is sugar B.
- the compound of the general formula (I) according to the present invention has an action of an anti-inflammatory drug because it effectively binds to the selectin protein present in leukocytes, and is widely used in the field of medicine. Be expected.
- the sulfated saccharide represented by the general formula ( ⁇ ) according to the present invention has the following general formula (Ila)
- the [D] is a hydroxyl group, a substituted hydroxyl group or sugar residue.
- Sugar residues include residues derived from sugars selected from monosaccharides, oligosaccharides and polysaccharides. Examples of the polysaccharide include those conventionally known, for example, glucose, galactose, mannose, N-acetyl darcosamine, N-acetyl galactosamine, N-acetyl methyl mannosamine and the like.
- Oligosaccharides include oligosaccharides composed of these monosaccharides, chondroitin sulfate, dermatan sulfate, heparin and the like. Polysaccharides include those obtained by highly polymerizing the aforementioned monosaccharides and oligosaccharides. These sugars may contain a sulfate group or a phosphate group. When [Z] and [D] are sugar residues, [Z] is preferably a sugar residue different from [D]. '
- the substituted hydroxyl group means one in which hydrogen of the hydroxyl group is substituted by a substituent, and specific examples thereof are described above.
- the sulfated saccharide represented by the above general formula (Ila) acts as a sugar chain acceptor and reacts with HO— (GlcNAc) — [Z] as a sugar chain donor.
- HO— (GlcNAc) — [Z] a sugar chain donor.
- a sulfated sugar chain can be extended to the sugar reducing terminal.
- a preferred sulfated sugar used as a sugar chain receptor in the present invention is p-nitrophenyl] 3-D_
- the sugar chain donor preferably used in the present invention is, for example, paranitrophenyl ⁇ -acetyldarcosamine ((G1cNAc)-[paraditrophenyl]).
- the sulfated saccharide of the general formula (II) can be produced.
- the reactants are usually used at a molar ratio of 1: 1. However, either of them may be used in excess.
- the reaction is carried out in the liquid phase and the reaction temperature ranges from 0 to 80 ° C, preferably from room temperature to 50 ° C.
- the enzyme used is N-acetylhexosaminidase (EC 3.2.1.52) or N-acetyl darcosaminidase (EC 3.2.1.52).
- the origins of these enzymes include mold, calf organs, pacteria, beans, yeast, and recombinant DNA.
- the enzyme can be used by being supported on various carriers. By using the enzyme supported on a carrier as described above, the reaction can be performed at low cost. Alginate polymer for the carrier And ribosomes.
- reaction product is obtained in an isolation yield of 1 to 80% based on the raw material.
- reaction product can be separated and purified by means of reverse phase chromatography, molecular sieving (gel filtration), and ion exchange resin.
- This reaction uses commonly used buffers such as phosphate buffer, Tris-HCl buffer, and HEPS buffer. Also, a hydrophilic organic solvent such as acetonitrile or methanol can be added to the buffer. The ratio is 0-90%, but preferably 10-50%. Rarely, solvents such as toluene-diethyl ether are also used, but in this case a two-phase system is used.
- the reaction is carried out in the range of 0 ° C to 80 ° C.
- the reaction temperature is desirably around room temperature to 50 ° C.
- the second sulfated sugar chain according to the present invention is represented by the following general formula (II).
- the sulfated sugar chain of the present invention is a sugar compound characterized by having a sulfated sugar chain on the reducing terminal side of the sugar.
- the sulfated sugar chain of the general formula (II) according to the present invention has an action of an anti-inflammatory drug because it effectively binds to a selectin protein present in leukocytes, and is widely used in the field of medicine. Is expected.
- Preferred according to the invention are sulfated sugars of the formula:
- p-Toluenephenyl j3-D- (6-sulfo) -N-acetyldarcosamine sodium salt (54 mg) and methyl a-D-darcoviranoside (500 mg) were added to a 50 mM sodium phosphate buffer solution ( ⁇ 6 0, 1 mL), add Aspergillus oryzae-derived D-N-acetyl to oxosaminidase (10.5 units) (EC.3.2.1.52, manufactured by Sigma) for 71 hours at 35 ° C. Incubated. The reaction was immersed in water at 100 ° C for 5 minutes to stop the reaction.
- reaction mixture was purified on a DEAE Sephadex A-25 column (eluent: water ⁇ 0.2 M ammonium acetate solution). Further purification was performed on a Dowex-50W-X8 column (H +) and finally by Bio-Gel P-2 chromatography. As a result, the target product, j3 -D- (6-sulf o ) -GlcNAc- (1 ⁇ 4) - a -Glc-0CH 3 to 9, 8 mg (17%) was obtained.
- a sulfated saccharide when a sulfated saccharide is used as a donor and another saccharide is used as an acceptor using N-acetylhexosaminidase, which is a commercially available enzyme, the non-reduced terminal is oxidized to the non-reducing terminal. A new sulfated saccharide with an extended saccharide was obtained.
- a new sulfated saccharide having a sulfated saccharide extended to the reducing end could be obtained.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Crystallography & Structural Chemistry (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/480,383 US20050004069A1 (en) | 2001-06-14 | 2002-03-20 | Novel sulfated saccharide and process for producing the same |
JP2003505347A JPWO2002103025A1 (ja) | 2001-06-14 | 2002-03-20 | 新規な硫酸化糖及びその製造方法 |
EP02705414A EP1408116A4 (en) | 2001-06-14 | 2002-03-20 | NEW SULFATED SACCHARIDE AND METHOD FOR THE PRODUCTION THEREOF |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001-180163 | 2001-06-14 | ||
JP2001180163 | 2001-06-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002103025A1 true WO2002103025A1 (fr) | 2002-12-27 |
Family
ID=19020625
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2002/002716 WO2002103025A1 (fr) | 2001-06-14 | 2002-03-20 | Nouveau saccharide sulfate et procede de production associe |
Country Status (4)
Country | Link |
---|---|
US (1) | US20050004069A1 (ja) |
EP (1) | EP1408116A4 (ja) |
JP (1) | JPWO2002103025A1 (ja) |
WO (1) | WO2002103025A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1541580A1 (en) * | 2002-07-10 | 2005-06-15 | Seikagaku Corporation | Sulfotransferase inhibitors |
WO2017154938A1 (ja) | 2016-03-09 | 2017-09-14 | 株式会社糖鎖工学研究所 | 硫酸基および/またはリン酸基を有する糖の製造方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0795560A1 (en) * | 1994-12-01 | 1997-09-17 | Seikagaku Corporation | Keratan sulfate oligosaccharide fraction and drug containing the same |
EP0798385A2 (en) * | 1996-03-29 | 1997-10-01 | Seikagaku Kogyo Kabushiki Kaisha (Seikagaku Corporation) | Method for producing sulfated lactosamine oligosaccharide |
EP0943688A2 (en) * | 1998-03-05 | 1999-09-22 | Seikagaku Corporation | Polypeptide of N-acetylglucosamine-6-0-sulfotransferase and DNA encoding the same |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9117523D0 (en) * | 1991-08-14 | 1991-10-02 | Unilever Plc | Di and tri saccharides, methods of making them and hair growth compositions containing them |
DE69521074T2 (de) * | 1994-03-30 | 2001-09-13 | Takara Shuzo Co., Ltd. | Transglykosylierungsverfahren zur Herstellung eines Kohlenhydrats oder eines Glykokonjugates |
-
2002
- 2002-03-20 US US10/480,383 patent/US20050004069A1/en not_active Abandoned
- 2002-03-20 JP JP2003505347A patent/JPWO2002103025A1/ja active Pending
- 2002-03-20 WO PCT/JP2002/002716 patent/WO2002103025A1/ja not_active Application Discontinuation
- 2002-03-20 EP EP02705414A patent/EP1408116A4/en not_active Withdrawn
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0795560A1 (en) * | 1994-12-01 | 1997-09-17 | Seikagaku Corporation | Keratan sulfate oligosaccharide fraction and drug containing the same |
EP0798385A2 (en) * | 1996-03-29 | 1997-10-01 | Seikagaku Kogyo Kabushiki Kaisha (Seikagaku Corporation) | Method for producing sulfated lactosamine oligosaccharide |
EP0943688A2 (en) * | 1998-03-05 | 1999-09-22 | Seikagaku Corporation | Polypeptide of N-acetylglucosamine-6-0-sulfotransferase and DNA encoding the same |
Non-Patent Citations (3)
Title |
---|
CHUN-HUNG LIN ET AL.: "Enzymatic synthesis and regeneration of 3'-phosphoadenosine 5'-phosphosulfate (PAPS) for regioselective sulfation of oligosaccharides", J. AM. CHEM. SOC., vol. 117, 1995, pages 8031 - 8032, XP002954169 * |
See also references of EP1408116A4 * |
ZENG X. ET AL.: "Synthesis of sulfated disaccharides by use of the transglycosylation of beta-D-N-acetylhexosaminidase", THE JAPANESE SOCIETY OF CARBOHYDRATE RESEARCH NENKAI YOSHISHU, 2 July 2001 (2001-07-02), pages 147, XP002954168 * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1541580A1 (en) * | 2002-07-10 | 2005-06-15 | Seikagaku Corporation | Sulfotransferase inhibitors |
EP1541580A4 (en) * | 2002-07-10 | 2010-05-19 | Seikagaku Kogyo Co Ltd | SULFOTRANSFERASE INHIBITORS |
US8288139B2 (en) | 2002-07-10 | 2012-10-16 | Seikagaku Corporation | Sulfotransferase inhibitors |
WO2017154938A1 (ja) | 2016-03-09 | 2017-09-14 | 株式会社糖鎖工学研究所 | 硫酸基および/またはリン酸基を有する糖の製造方法 |
KR20180120186A (ko) * | 2016-03-09 | 2018-11-05 | 가부시키가이샤 도우사 고가쿠 겐큐쇼 | 설페이트기 및/또는 포스페이트기를 갖는 당의 제조방법 |
JPWO2017154938A1 (ja) * | 2016-03-09 | 2019-01-10 | 株式会社糖鎖工学研究所 | 硫酸基および/またはリン酸基を有する糖の製造方法 |
KR102468224B1 (ko) * | 2016-03-09 | 2022-11-17 | 가부시키가이샤 도우사 고가쿠 겐큐쇼 | 설페이트기 및/또는 포스페이트기를 갖는 당의 제조방법 |
JP7401882B2 (ja) | 2016-03-09 | 2023-12-20 | 株式会社糖鎖工学研究所 | 硫酸基を有する糖の製造方法 |
Also Published As
Publication number | Publication date |
---|---|
EP1408116A1 (en) | 2004-04-14 |
US20050004069A1 (en) | 2005-01-06 |
EP1408116A4 (en) | 2006-11-08 |
JPWO2002103025A1 (ja) | 2005-04-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Krasnova et al. | Oligosaccharide synthesis and translational innovation | |
Sabesan et al. | Combined chemical and enzymatic synthesis of sialyloligosaccharides and characterization by 500-MHz and proton and carbon-13 NMR spectroscopy | |
Huang et al. | Stereodirecting effect of C5-carboxylate substituents on the glycosylation stereochemistry of 3-deoxy-d-manno-oct-2-ulosonic acid (Kdo) thioglycoside donors: Stereoselective synthesis of α-and β-Kdo glycosides | |
Boons et al. | Recent advances in O-sialylation | |
Wang et al. | Preactivation‐based, one‐pot combinatorial synthesis of heparin‐like hexasaccharides for the analysis of heparin–protein interactions | |
Wong | Mimics of complex carbohydrates recognized by receptors | |
Nilsson | Enzymatic synthesis of oligosaccharides | |
Izumi et al. | Microbial Glycosyltransferases for Carbohydrate Synthesis: α-2, 3-Sialyltransferase from Neisseria g onorrheae | |
Virgilio et al. | Enzymatic synthesis of natural and 13C enriched linear poly-N-acetyllactosamines as ligands for galectin-1 | |
Pozsgay et al. | Synthesis of kojidextrins and their protein conjugates. Incidence of steric mismatch in oligosaccharide synthesis | |
CA2385295A1 (en) | Novel fucosylated oligosaccharides and process for their preparation | |
Wang et al. | Reagent controlled glycosylations for the assembly of well-defined pel oligosaccharides | |
Krog-Jensen et al. | Stereospecific synthesis of β-d-fructofuranosides using thioglycoside donors and internal aglycon delivery | |
Santra et al. | Regioselective one-pot multienzyme (OPME) chemoenzymatic strategies for systematic synthesis of sialyl core 2 glycans | |
Nilsson | Synthesis with glycosidases | |
Hansson et al. | Syntheses of Anomerically Phosphodiester-Linked Oligomers of the Repeating Units of the Haemophilus i nfluenzae Types c and f Capsular Polysaccharides | |
Codée et al. | The synthesis of well-defined heparin and heparan sulfate fragments | |
Phang et al. | Synthesis of type-I and type-II lacNAc-repeating oligosaccharides as the backbones of tumor-associated lewis antigens | |
Zhang et al. | Stereoselective Synthesis of β-C-Glycosides of 3-Deoxy-d-manno-oct-2-ulosonic Acid (Kdo) via SmI2-Mediated Reformatsky Reactions | |
Liu et al. | Glycan assembly strategy: from concept to application | |
Yan et al. | Simplifying oligosaccharide synthesis: efficient synthesis of lactosamine and siaylated lactosamine oligosaccharide donors | |
Xu et al. | Stereoselective synthesis of the trisaccharide moiety of ganglioside HLG-2 | |
Oscarson et al. | Chemical syntheses of inulin and levan structures | |
WO2002103025A1 (fr) | Nouveau saccharide sulfate et procede de production associe | |
Lio et al. | Chemoenzymatic synthesis of spacer-linked oligosaccharides for the preparation of neoglycoproteins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003505347 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002705414 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2002705414 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10480383 Country of ref document: US |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2002705414 Country of ref document: EP |